Chicken factor for Genavia
Monday, 09 March, 2009
Private Auckland biotech Genavia Therapeutics has purchased the rights to use technology developed by California company Origen to manufacture and market Factor VIII proteins in chicken eggs.
Factor VIII, an essential clotting protein missing in people with haemophilia A, is generally produced using cell culture technology or is extracted from donors.
Origen has developed technology using transgenic chicken whites to produce therapeutic proteins, including Factor VIII, Factor VII and Factor IX, the missing ingredient in haemophilia B.
The technology promises to produce proteins at a greatly reduced price than current methods, the companies said in a joint statement.
Genavia, which was established last year, concentrates on developing economical therapeutic options in areas that are currently under-served. Origen’s avian transgenic platform is aimed at recombinant protein therapeutics, including monoclonal antibodies.
Under the agreement, Origen will receive equity in Genavia, royalties and milestone payments.
Placebo pain relief works differently across the human body
Researchers have used placebo pain relief to uncover a map-like system in the brainstem that...
COVID infection ages blood vessels, particularly in women
Blood vessels gradually become stiffer with age, but a new study by international researchers...
Lead exposure linked to memory problems, even decades later
Historic lead levels from the era of leaded petrol may be contributing to cognitive issues 50...
